Physician profile
Queeneth Egwu
NPI 1194338160
$631.75
in general payments reported to CMS, 2019-2025
10 companies · $285 in 2025
The $285 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $93.91 · 2023: $96.82 · 2024: $156 · 2025: $285.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $538.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $537.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $203.23 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $115.46 | 2023-2024 | Farxiga, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $99.08 | 2024 | Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $73.92 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $40.19 | 2025 | Abilify Asimtufii, Abilify Maintena, Rexulti |
| Vanda Pharmaceuticals INC. | $24.97 | 2025 | Fanapt |
| Lilly USA, LLC | $24.46 | 2024 | Mounjaro |
| Grt US Holding, INC. | $19.99 | 2022 | |
| Seqirus USA INC | $16.84 | 2025 | Fluad, Flucelvax |
| Novartis Pharmaceuticals Corporation | $13.61 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Queeneth Egwu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.